Norditropin Flexpro (Somatropin)

Somatropin, the active ingredient in Norditropin Flexpro, is a Human growth hormone presented as a solution for injection for subcutaneous use. It treats growth hormone deficiency in children and adults and is indicated for several growth‑related disorders. It is used under medical supervision to promote linear growth in pediatric patients and to improve body composition, bone density, and metabolic parameters in adult patients with confirmed deficiency.

GNH USA supplies Norditropin Flexpro as a licensed, GDP‑compliant supplier serving hospitals, pharmacies and clinics worldwide.

Norditropin Flexpro, a recombinant human growth hormone, is used to address conditions characterized by growth hormone deficiency or impaired growth. - Growth hormone deficiency in children: increases growth velocity and helps achieve normal adult height. - Growth hormone deficiency in adults: improves body composition, bone density, and metabolic health. - Turner syndrome: promotes linear growth and improves final height in affected females. - Chronic renal insufficiency: supports growth in pediatric patients with renal‑related growth failure. - Prader‑Willi syndrome: enhances growth and may improve body composition in children. - Short stature associated with Noonan syndrome: stimulates growth to reduce height deficit.

Somatropin therapy may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Injection site pain or erythema. - Headache. - Joint or muscle aches. - Peripheral edema.

Serious or Rare Side Effects: - Intracranial hypertension. - Slipped epiphysis (growth plate closure). - Hyperglycemia or new‑onset diabetes. - Severe allergic reaction (anaphylaxis).

When prescribing Norditropin Flexpro, clinicians should consider several safety measures. - Monitor glucose levels: patients with diabetes may experience altered glycemic control. - Assess thyroid function: hypothyroidism can blunt growth response. - Screen for intracranial hypertension: discontinue if symptoms develop. - Evaluate for malignancy: use with caution in patients with active cancer. - Avoid use in active proliferative retinopathy: may worsen condition. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Somatropin may interact with other medicines, requiring attention to dosing and monitoring.

Major Interactions (Avoid): - Concurrent high‑dose glucocorticoids: may reduce somatropin efficacy. - Insulin or oral hypoglycemics: increased risk of hypoglycemia.

Moderate Interactions (Monitor Closely): - Oral estrogen therapy: may alter IGF‑1 response. - Thyroid hormone replacement: requires dose adjustment of levothyroxine. - Anticonvulsants (e.g., carbamazepine): may increase somatropin clearance.